Education and Training
- M.S., University of North Carolina at Chapel Hill, 1979
- B.S., East Carolina University, 1977
Espinel-Ingroff, A., A. Fothergill, M. Ghannoum, E. Manavathu, L. Ostrosky-Zeichner, M. Pfaller, M. Rinaldi, W. Schell, and T. Walsh. “Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole..” Journal of Clinical Microbiology 43, no. 10 (October 2005): 5243–46. https://doi.org/10.1128/JCM.43.10.5243-5246.2005.
Alexander, Barbara D., Wiley A. Schell, Jackie L. Miller, Gwynn D. Long, and John R. Perfect. “Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole..” Transplantation 80, no. 6 (September 2005): 868–71. https://doi.org/10.1097/01.tp.0000173771.47698.7b.
Chang, Christopher Y., Wiley A. Schell, John R. Perfect, and Gregory F. Hulka. “Novel use of a swimming pool biocide in the treatment of a rare fungal mastoiditis..” The Laryngoscope 115, no. 6 (June 2005): 1065–69. https://doi.org/10.1097/01.mlg.0000163338.45700.fe.
Steinbach, William J., Nina Singh, Jackie L. Miller, Daniel K. Benjamin, Wiley A. Schell, Joseph Heitman, and John R. Perfect. “In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients..” Antimicrobial Agents and Chemotherapy 48, no. 12 (December 2004): 4922–25. https://doi.org/10.1128/AAC.48.12.4922-4925.2004.
Jiménez-Expósito, M. J., G. Torres, A. Baraldés, N. Benito, F. Marco, J. C. Paré, A. Moreno, et al. “Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment..” Clin Infect Dis 39, no. 7 (October 1, 2004): e70–73. https://doi.org/10.1086/424018.
Steinbach, William J., Daniel K. Benjamin, Scott A. Trasi, Jackie L. Miller, Wiley A. Schell, Aimee K. Zaas, W Michael Foster, and John R. Perfect. “Value of an inhalational model of invasive aspergillosis..” Med Mycol 42, no. 5 (October 2004): 417–25. https://doi.org/10.1080/13693780410001712034.
Steinbach, William J., John R. Perfect, Wiley A. Schell, Thomas J. Walsh, and Daniel K. Benjamin. “In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection..” Antimicrobial Agents and Chemotherapy 48, no. 9 (September 2004): 3217–25. https://doi.org/10.1128/AAC.48.9.3217-3225.2004.
Miwa, Takuya, Yukinobu Takagi, Makiko Shinozaki, Cheol-Won Yun, Wiley A. Schell, John R. Perfect, Hidehiko Kumagai, and Hisanori Tamaki. “Gpr1, a putative G-protein-coupled receptor, regulates morphogenesis and hypha formation in the pathogenic fungus Candida albicans..” Eukaryotic Cell 3, no. 4 (August 2004): 919–31. https://doi.org/10.1128/EC.3.4.919-931.2004.
Odds, Frank C., Mary Motyl, Roberto Andrade, Jacques Bille, Emilia Cantón, Manuel Cuenca-Estrella, Amanda Davidson, et al. “Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species..” Journal of Clinical Microbiology 42, no. 8 (August 2004): 3475–82. https://doi.org/10.1128/JCM.42.8.3475-3482.2004.
Steinbach, William J., Wiley A. Schell, Jill R. Blankenship, Chiatogu Onyewu, Joseph Heitman, and John R. Perfect. “In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus..” Antimicrob Agents Chemother 48, no. 5 (May 2004): 1664–69. https://doi.org/10.1128/aac.48.5.1664-1669.2004.